Lacosamid Viatris (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyper‑excitable neurons and decreasing repetitive firing that leads to seizures.

The specific dose and titration schedule are determined by the prescribing clinician based on individual patient factors such as age, renal function, and concomitant medications. The prescriber sets the appropriate regimen.

Safety data for lacosamide during pregnancy and lactation are limited; the drug is classified with an unknown pregnancy category. Use only if the potential benefit outweighs the risk, and discuss with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Compared with other sodium‑channel blockers such as carbamazepine or oxcarbazepine, lacosamide selectively enhances slow inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑drug interactions. Clinical choice depends on efficacy, tolerability, and patient‑specific factors.

Lacosamid Viatris should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

The product is taken orally, usually as a tablet or oral solution, and should be swallowed with water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any required dose adjustments.

Serious adverse reactions include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions, hypersensitivity, and suicidal thoughts. Patients should seek immediate medical attention if they experience palpitations, rash, or mood changes.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking other sodium‑channel‑blocking agents, unless a clinician determines the benefits outweigh the risks.